Objective(s): Central nervous system demyelination is the main feature of multiple sclerosis (MS). The most important unmet need in MS is use of treatments that delay the progression of the disease. Leucine-rich repeat and Immunoglobulin-like domain containing NOGO receptor-interacting protein 1(LINGO-1) have been known as inhibitors of oligodendrocyte differentiation and myelination.Materials and Methods: We investigated LINGO-1 antibody effects on remyelination and neurobehavioral deficit using cuprizone-induced demyelination. Animals were randomly divided into three groups (n = 10): (1) Control group; received the regular diet, (2) CPZ group; normal saline was injected intraperitoneally, and (3) Treatment group; LINGO-1 antibody (10 mg/...
A central question in the development of treatments for demyelinating diseases is how to reverse the...
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young p...
One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeut...
Demyelinating diseases, such as multiple sclerosis, are characterized by the loss of the myelin shea...
LINGO-1 (leucine-rich repeat and Ig domain containing NOGO receptor interacting protein-1) is a nega...
Objective: Repair of demyelinated axons in diseases such as multiple sclerosis requires activation o...
Introduction: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous syst...
Acute optic neuritis (AON) is characterized by inflammatory injury to the optic nerve and is frequen...
Anti-LINGO-1 is a monoclonal antibody antagonist of LINGO-1, an oligodendrocyte differentiation and ...
BACKGROUND: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the...
Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative regu...
Two hallmarks of chronic multiple sclerosis lesions are the absence of significant spontaneous remye...
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS)...
Though promoting remyelination in multiple sclerosis (MS) has emerged as a promising therapeutic str...
Background Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the ...
A central question in the development of treatments for demyelinating diseases is how to reverse the...
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young p...
One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeut...
Demyelinating diseases, such as multiple sclerosis, are characterized by the loss of the myelin shea...
LINGO-1 (leucine-rich repeat and Ig domain containing NOGO receptor interacting protein-1) is a nega...
Objective: Repair of demyelinated axons in diseases such as multiple sclerosis requires activation o...
Introduction: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous syst...
Acute optic neuritis (AON) is characterized by inflammatory injury to the optic nerve and is frequen...
Anti-LINGO-1 is a monoclonal antibody antagonist of LINGO-1, an oligodendrocyte differentiation and ...
BACKGROUND: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the...
Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative regu...
Two hallmarks of chronic multiple sclerosis lesions are the absence of significant spontaneous remye...
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS)...
Though promoting remyelination in multiple sclerosis (MS) has emerged as a promising therapeutic str...
Background Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the ...
A central question in the development of treatments for demyelinating diseases is how to reverse the...
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young p...
One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeut...